DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Combat Readiness � Medical
  4. Research Highlights/News
  5. 2022 Combat Readiness � Medical Research Program

Combat Readiness � Medical

NEWS RELEASE

Released: March 18, 2022

Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Combat Readiness � Medical Research Program
Anticipated Funding Opportunities for Fiscal Year 2022 (FY22)

The FY22 Defense Appropriation provides funding for the CRRP to support military-relevant advanced technology and therapeutic research related to forward-deployable solutions that can promptly address life-threatening injuries, medical threats, and treatments for Service Members in current and future battlefield settings. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The CRRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY22 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY22 CRRP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.

The FY22 CRRP will solicit research applications addressing at least one of the Focus Areas described below. The Focus Areas broadly describe current needs to ensure readiness for delivering front-line care in combat situations and for delivering medical damage control capability, assets, and lifesaving interventions to address the emerging needs of the Warfighter and Service medics during prolonged and en route care in austere and combat environments, including the acute and early management of combat-related trauma at the point of injury.

Applications submitted to the FY22 CRRP must address one or more of the following Focus Areas:

  • Solutions to enhance Warfighter readiness, such as solutions to address:
    • Sleep disorders
    • Myalgic encephalomyelitis/chronic fatigue syndrome
    • Service-related post-traumatic arthritis
    • Eating disorders
    • Sarcoidosis
    • Valley fever
    • Complementary health measures to accelerate return to duty
    • Regenerative medicine
  • Solutions to enhance combat care delivery throughout the far-forward environment, such as:
    • Telemedicine solutions that enable medical capabilities at far-forward battlespace locations worldwide
    • Medical simulation technology that support sustainment of critical skills and medical decision-making
    • Blood products, including freeze-dried plasma and platelets
    • Ruggedized oxygen generation systems for medical use
    • Solutions for the assessment of mild traumatic brain injury, to include portable and hand-held detection devices
    • Extracorporeal life support
    • Initial treatment and transport of patients with highly transmissible infectious disease
  • Wound care solutions for complex trauma and tissue regeneration that span the operational medical care continuum or roles of care (e.g., acute through chronic care), such as:
    • Multi-modal wound care solutions that provide a combination of hemostasis, wound healing, infection prevention, and/or analgesia
    • Repair and restoration of genitourinary injury and tissue damage

The Areas of Encouragement were identified as capability and knowledge gaps that are of high priority and programmatic relevance and can be found appended to the FY22 funding opportunity announcement. Investigators are strongly encouraged to propose research ideas that specifically address one of the FY22 Areas of Encouragement within each Focus Area (if applicable).



Award Mechanism Eligibility Key Mechanism Elements Funding
Rapid Development and Translational Research Award (RDTRA) Extramural and intramural applicants
  • Independent investigators at all academic levels (or equivalent)
  • Submission of a preproposal is required; application submission is by invitation only.
  • Supports high-impact research that will accelerate the movement of promising ideas into clinical applications, including healthcare products, technologies, and/or practice guidelines.
  • Proposed research must have the potential for rapid development and translation of applicable advances for improving medical readiness, mitigating fatalities, optimally treating life-threatening injuries, and promoting positive long-term outcomes for military health and medicine, as well as the general public.
  • Supports preclinical research, clinical research, and small-scale clinical trials (e.g., first in human, phase 1/1b). Fundamental basic research, phase 2/3 clinical trials are not supported under this funding opportunity.
  • Proposed research must address at least one of the FY22 CRRP Focus Areas.
  • Different funding options are available. Applicants may apply for either the RDTRA, or the RDTRA with Option. It is the responsibility of the Principal Investigator to select the funding option that is most appropriate for the research proposed.
    • For applications proposing an RDTRA with Option, each phase of research must be a distinct research effort with non-overlapping period of performance, research outcomes/milestones, and budget. Research products from the RDTRA base award shall be leveraged in the subsequent Option phase.
    • Exercise of the Option is contingent on the availability of sufficient future congressional appropriations to the CRRP, alignment of the proposed research during the Option to that fiscal year�s congressional language, and acceptable performance by the recipients.
 RDTRA
  • Maximum funding of $2,200,000 for total costs (to include direct and indirect costs).
  • Maximum period of performance is 2 years.

RDTRA with Option

  • Maximum funding of $2,200,000 (RDTRA) and $1,000,000 (Option) for total costs (to include direct and indirect costs).
  • Maximum period of performance is 2 years for the RDTRA and 1 year for the Option.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the funding opportunity announcement is released.  For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the CRRP or other CDMRP-administered programs, please visit the CDMRP website (https://CDMRP.HEALTH.MIL).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


Last updated Tuesday, November 12, 2024